Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Sei Investments Co.

Sei Investments Co. cut its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 70.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,079 shares of the company's stock after selling 35,414 shares during the quarter. Sei Investments Co.'s holdings in Syndax Pharmaceuticals were worth $200,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in SNDX. E Fund Management Co. Ltd. increased its stake in Syndax Pharmaceuticals by 14.4% in the 4th quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company's stock worth $167,000 after purchasing an additional 1,583 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Syndax Pharmaceuticals by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company's stock worth $239,000 after purchasing an additional 1,732 shares in the last quarter. R Squared Ltd purchased a new stake in Syndax Pharmaceuticals in the fourth quarter worth about $26,000. Y Intercept Hong Kong Ltd grew its stake in Syndax Pharmaceuticals by 2.5% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 83,297 shares of the company's stock worth $1,101,000 after purchasing an additional 1,995 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in Syndax Pharmaceuticals by 1.2% during the fourth quarter. Bank of New York Mellon Corp now owns 224,261 shares of the company's stock worth $2,965,000 after acquiring an additional 2,759 shares in the last quarter.

Remove Ads

Insider Activity

In other news, CEO Michael A. Metzger sold 13,288 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the sale, the chief executive officer now directly owns 300,121 shares in the company, valued at approximately $4,651,875.50. This trade represents a 4.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Neil Gallagher sold 4,618 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the transaction, the insider now owns 85,095 shares of the company's stock, valued at approximately $1,318,972.50. This trade represents a 5.15 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,683 shares of company stock worth $336,087. Corporate insiders own 4.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. HC Wainwright restated a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. JPMorgan Chase & Co. raised their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research note on Thursday, March 20th. StockNews.com raised shares of Syndax Pharmaceuticals to a "sell" rating in a report on Thursday, April 10th. Citigroup reduced their price objective on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Finally, Scotiabank decreased their target price on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $36.20.

Syndax Pharmaceuticals Trading Up 0.8 %

Shares of Syndax Pharmaceuticals stock traded up $0.09 on Tuesday, hitting $11.33. 1,354,467 shares of the company traded hands, compared to its average volume of 1,573,456. Syndax Pharmaceuticals, Inc. has a 52 week low of $9.66 and a 52 week high of $25.07. The company has a market cap of $974.88 million, a PE ratio of -3.12 and a beta of 1.28. The stock's 50 day moving average price is $13.60 and its 200-day moving average price is $15.26.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to analyst estimates of $86.32 million. As a group, research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).